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Patients with rheumatoid arthritis (RA)
have beneﬁted from an unprecedented
treatment improvement over the last two
decades. Taking the disease seriously, with
earlier and more intensive treat-to-target
strategies and new treatment options with
biologicals, has led to a better long-term
disease control. Classical antirheumatic
therapies, primarily directed against the
inﬂammatory/immunological processes
that determine RA disease activity, are suc-
cessfully improving pain and the severe
clinical and functional burden patients are
confronted with. Moreover, one of the
most important previous hallmarks of this
disease, severe joint destruction with sub-
sequent deformations, can now in most
cases be prevented thanks to the develop-
ment of new treatment strategies and the
introduction of novel therapeutics. The
Cobra trial1 demonstrated the existence of
a window of opportunity for preventing
joint damage in early RA and the Attract
trial2 showed an arrest in further X-ray
damage—at least at the group level—in
severe methotrexate (MTX) refractory
disease treated with inﬂiximab, which was
unprecedented at that time. Thanks to
more effective treatments prevention of
further damage was reported and even, in
a (small) number of cases, what could be
considered as healing of erosions.3 4
Other publications focused on a potential
uncoupling between controlling inﬂamma-
tion and damage. Prevention of X-ray pro-
gression appeared possible independent
from successfully reducing disease activity,
at least with certain therapeutics.5 Despite
the fact that today joint damage can be
prevented in the large majority of cases, it
is still an important determinant in the
evaluation of RA treatment efﬁcacy given
the link between X-ray progression and
future physical disability.6
Takeuchi et al7 demonstrate an add-
itional inhibitory effect on the progression
of bone erosions (not joint space narrow-
ing) of three different dosages of denosu-
mab on top of the traditional RA
treatment over a 12-month period in
Japanese patients with RA, conﬁrming
results reported already 8 years ago by
Cohen et al8 in North America. Although
the erosive changes are relatively small
and a certain ‘hang-over’ of MTX is pos-
sible, this study has clear strengths like the
placebo-controlled design, the relatively
early study population, the similar evolu-
tion of disease activity markers across
treatment arms and the documentation
of improved bone-turnover and not
cartilage-turnover markers, conﬁrming the
X-ray results. The results are convincing
even though the study population con-
sisted of patients with relatively low
disease activity. One wonders what this
would have been in more active patients
or with less glucocorticoid use. On the
other hand, the treat-to-target approach
was not applied, making the relevance of
the study results for daily practice some-
what uncertain. Nevertheless, this study
conﬁrms the predeﬁned proof of concept
that denosumab can be of help in prevent-
ing joint erosions in RA.
Earlier attempts to prevent (cartilage)
damage in RA with therapeutic agents not
speciﬁcally targeting joint inﬂammation
were already initiated >15 years ago,
focusing mainly on metalloproteinase
inhibitors. A nice overview on this topic
was written by Close9 in this journal in
2001. Questions about representativeness
of the animal models the drugs were
tested in, lack of sensitivity in outcome
measurements, and speciﬁcity and safety
issues of the drugs tested, were raised.
Inefﬁcacy of minocycline—known also
for its collagenase inhibitory properties—
in preventing X-ray damage in RA10 and
the preliminary discontinuation of the
Trocade trial with a MMP-1 inhibitor
despite promising explorative ﬁndings,11
precluded further research along this
therapeutic pathway in RA because of an
apparent unfavourable risk–beneﬁt proﬁle.
Currently, matrix metalloproteinase-3 is
still under investigation although not so
much as a direct therapeutic target but
rather as a predictive biomarker for joint
damage and therefore as an additional
measurement instrument in treat-to-target
strategies.12 13 In the meantime, attempts
to separately tackle bony erosions were
continued at a smaller scale and with
mixed success, with denosumab and with
bisphosphonates14 and parathormone
(PTH),15 but apparently without real
breakthrough and without any further
implementation in daily practice.
While the idea of additional prevention
of cartilage and/or bone destruction with
agents not directly targeting inﬂammation
is being investigated already for more than
two decades and is again brought to our
attention with this denosumab trial, one
could question the relevance of this com-
plementary approach given the successful-
ness of current RA treatment standards.
There is no doubt that avoiding the
occurrence of joint erosions is still an
important issue. Joint erosions historically
have always been perceived to be a critical
indicator of permanent future disability in
patients with RA, although data suggest
also that joint space narrowing, occurring
early in disease process, may be a more
important determinant of irreversible
physical disability.6 16 On the other hand,
erosions are more prevalent than joint
space narrowing in early RA and a recent
study suggested existing erosions in a
single joint are associated with future joint
space narrowing making it clear that tack-
ling both bone and cartilage damage is
important, especially in early disease.
Interestingly, these data derived from the
PREMIER study17 also suggested that the
effect of pre-existing erosions on future
joint space narrowing, documented in the
MTX+adalimumab (ADA) and the ADA
monotherapy group, was at least partly
independent from the presence of clinical
synovitis.
Thanks to the availability of effective
therapeutic strategies we are more success-
ful in controlling disease activity than ever
before, but we should not forget to evalu-
ate joint damage as an objective and
cumulative readout of treatment effective-
ness. Swollen joint counts and all disease
activity measurement instruments includ-
ing swollen joints, as well as acute phase
reactants, are still robustly associated with
radiographic damage.18 This highlights
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the importance of the ongoing discussion
about the deﬁnition of ‘real remission’
and how to evaluate this in daily prac-
tice19 as well as further research on how
to implement effective intensive treatment
strategies as quickly as possible, especially
in early disease.20
Perhaps not surprisingly, in trials with
the more recently developed tumour
necrosis factor blockers like golimumab it
appeared more difﬁcult to demonstrate a
signiﬁcant radiographic beneﬁt from the
study drug because X-ray progression in
the so-called MTX-refractory study popu-
lation was globally lower than expected.21
The latter ﬁndings led to an important
viewpoint paper by Landewé et al22
focusing on trial design and statistical
challenges when evaluating patients with
RA and measuring treatment efﬁcacy,
especially efﬁcacy based on X-ray out-
comes. Dr Landewé correctly states that
we can no longer hang on to the classical
enrichment techniques selecting very
active patients with a severe risk proﬁle
for inclusion in trials, with the aim of
demonstrating superiority in damage
control of one treatment over another,
without serious ethical problems in an era
where many effective alternative therapies
are available. He proposes to replace
‘inhibition of radiographic progression’ by
‘maintaining structural integrity’ as an
outcome parameter in clinical trials.
While the focus of this paper was on
methodological issues as a consequence of
the limited radiographic progression in
clinical trials, this seems perfectly in
accordance with our own experiences in
daily practice, where early intensive step
down and treat-to-target strategies are
capable of bringing RA disease activity
under control in the vast majority of
patients, making X-ray damage little by
little a minor problem.23 For the subset of
patients refractory to optimal initial treat-
ment, today several additional treatments
are available to control disease activity
and in this way avoid radiographic
progression.
In view of preventing radiographic
damage and future disability it is clear
that aspects of timely treatment and
avoiding treatment delay,24 as well as per-
sonalised communication with individual
patients about their fears and beliefs, and
issues related to the implementation of
early intensive treatments in daily prac-
tice25 26 are at least as important as the
introduction of new and sophisticated
medication. Some of us might still tend to
adapt their treatment choices based on
markers of a bad prognosis in terms of
future X-ray damage. Unfortunately
however, current prediction matrices com-
bining several of these markers in order to
improve their predictive capacity still do
not perform adequately when used in
daily practice27 probably as a consequence
of the growing application, although ﬂex-
ibly, of the treat-to-target principle. From
our point of view, pending the discovery
of more adequate prognostic biomarkers
allowing personalised treatment stratiﬁca-
tion, all patients with RA should be
treated intensively and any symptoms and
signs pointing to remaining disease activ-
ity should be taken seriously, irrespective
of the patient’s traditional risk proﬁle. We
agree with the mantra of ‘maintaining
structural integrity’ also in the present
treatment era, but would like to expand
this towards ‘for as many patients as pos-
sible’ and hopefully allowing ‘mainten-
ance of optimal societal participation’.
A last and very important issue to con-
sider is the eventual additional cost for the
introduction of denosumab as an adjuvant
therapy for RA in an era where societal
expenditures for biologicals are already very
high and even utopic in many countries of
our world. It is questionable if cost-
effectivity would ever be reached taking into
consideration the treatment goals already
achieved using the present armamentarium.
Probably, for most patients a more adequate
implementation of the current knowledge
on how to induce and maintain disease
control would be more cost-effective than
trying to tackle additionally the progression
of erosions with denosumab. Of course
besides improving inﬂammation and pre-
venting joint damage, adequate RA manage-
ment involves also the prevention and
treatment of associated co-morbidities and
safety issues that might occur with any add-
itional therapy. The proposed additional
denosumab treatment could, apart from pre-
venting joint erosions, in certain patients
also constitute a therapy for RA-associated
osteoporosis, as suggested in the current
paper7 reporting also increased bone
density. One could therefore consider to
reserve such therapy for those patients with
RA with a particularly high fracture risk, in
order to improve the cost-effectiveness.
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